Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
CLDI.WS was delisted on the 17th of October, 2024.
21 hedge funds and large institutions have $1.64M invested in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 0 increasing their positions, 5 reducing their positions, and 6 closing their positions.
45% more capital invested
Capital invested by funds: $1.13M → $1.64M (+$511K)
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$119K |
| 2 |
ETH
Exos TFP Holdings
New York
|
+$19.2K |
| 3 |
SOA
Sea Otter Advisors
Miami,
Florida
|
+$891 |
| 4 |
CS
Clear Street
New York
|
+$356 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$9 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Segantii Capital Management
Hong Kong
|
-$262K |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$38.4K |
| 3 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$31.6K |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
-$30.1K |
| 5 |
ICM
Ionic Capital Management
New York
|
-$29.2K |
CLDI.WS Hedge Fund Activity: Q3 2023 in Review
21 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) for Q3 2023, worth a combined $1.64M — up 45% from $1.13M a quarter earlier.
Fund positioning in CLDI.WS was balanced in Q3 2023: 6 funds opened new positions, 6 closed out, 0 added to existing stakes and 5 trimmed.
The largest buyer was Shaolin Capital Management, opening a new position worth an estimated $119K. The largest seller was Segantii Capital Management, exiting entirely with an estimated $262K sold.
- 21 institutional investors held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $1.64M of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 stock for Q3 2023, up 45% quarter-over-quarter.
- 6 funds opened new Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 positions in Q3 2023 and 6 closed out, a net change of 0 holders.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 buyer in Q3 2023 was Shaolin Capital Management, an estimated $119K added.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 seller in Q3 2023 was Segantii Capital Management, an estimated $262K sold.
Based on aggregated 13F filings for Q3 2023.